In vivo clearance of hepatitis C virus nonstructural 3/4A-expressing hepatocytes by DNA vaccine-primed cytotoxic T lymphocytes
- PMID: 16288375
- DOI: 10.1086/498218
In vivo clearance of hepatitis C virus nonstructural 3/4A-expressing hepatocytes by DNA vaccine-primed cytotoxic T lymphocytes
Abstract
A key question in the development of a therapeutic vaccine against hepatitis C virus (HCV) is whether vaccine-primed T cells enter the liver and eliminate HCV-expressing hepatocytes. In the absence of an infectious small-animal model, we evaluated liver homing of vaccine-primed T cells in mice with transient hepatic transgene expression of the HCV nonstructural 3/4A (NS3/4A) protein. We found that T cells primed by transdermal DNA-based vaccination entered the liver and cleared NS3/4A-expressing hepatocytes in transiently transgenic CD8(+/+) mice but not in CD8(-/-) mice. Hence, peripherally primed NS3/4A-specific CD8(+) T cells home to the liver and clear HCV protein-expressing hepatocytes.
Similar articles
-
Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene.Gene Ther. 2004 Mar;11(6):522-33. doi: 10.1038/sj.gt.3302184. Gene Ther. 2004. PMID: 14999224
-
Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo.Gene Ther. 2003 Apr;10(8):686-99. doi: 10.1038/sj.gt.3301933. Gene Ther. 2003. PMID: 12692597
-
Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain.J Immunol. 2011 Feb 15;186(4):2355-64. doi: 10.4049/jimmunol.1001877. Epub 2011 Jan 21. J Immunol. 2011. PMID: 21257961
-
Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses.Immunol Rev. 2011 Jan;239(1):99-108. doi: 10.1111/j.1600-065X.2010.00977.x. Immunol Rev. 2011. PMID: 21198667 Review.
-
[Novel vaccines against M. tuberculosis].Kekkaku. 2006 Dec;81(12):745-51. Kekkaku. 2006. PMID: 17240920 Review. Japanese.
Cited by
-
Status of hepatitis C virus vaccination: Recent update.World J Gastroenterol. 2016 Jan 14;22(2):862-73. doi: 10.3748/wjg.v22.i2.862. World J Gastroenterol. 2016. PMID: 26811632 Free PMC article. Review.
-
Synthetic DNA immunogen encoding hepatitis B core antigen drives immune response in liver.Cancer Gene Ther. 2012 Nov;19(11):779-87. doi: 10.1038/cgt.2012.61. Epub 2012 Oct 5. Cancer Gene Ther. 2012. PMID: 23037809 Free PMC article.
-
Cleavage of the IPS-1/Cardif/MAVS/VISA does not inhibit T cell-mediated elimination of hepatitis C virus non-structural 3/4A-expressing hepatocytes.Gut. 2009 Apr;58(4):560-9. doi: 10.1136/gut.2007.147264. Epub 2008 Aug 8. Gut. 2009. PMID: 18689426 Free PMC article.
-
HCV p7 as a novel vaccine-target inducing multifunctional CD4+ and CD8+ T-cells targeting liver cells expressing the viral antigen.Sci Rep. 2019 Oct 1;9(1):14085. doi: 10.1038/s41598-019-50365-z. Sci Rep. 2019. PMID: 31575882 Free PMC article.
-
Treatment of hepatitis C virus infection.World J Gastroenterol. 2007 Apr 7;13(13):1897-905. doi: 10.3748/wjg.v13.i13.1897. World J Gastroenterol. 2007. PMID: 17461488 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials